Tychon Bioscience is a biotechnology company commercializing adaptive immunotherapy technology. Its PARs harnesses the power of protein dimerization to produce chemically self-assembling nanorings that form a construct to combine a patient’s T-lymphocytes and a host of cancer-seeking antigens creating various cell therapies with selective